Palmitoyl Tripeptide-1
Pal-GHK · Palmitoyl Oligopeptide · Palmitoyl-Gly-His-Lys · Biopeptide CL · Matrixyl 3000 component
Last updated
At a glance
Overview
Pal-GHK (palmitoyl tripeptide-1) is the workhorse matrikine peptide of modern topical anti-aging — the active that sits underneath tretinoin, microneedling, and the rest of an aesthetic stack and quietly drives collagen, elastin, and hyaluronic-acid synthesis in the dermal fibroblast layer. Looksmaxxers and skin-focused users reach for it because the underlying signal — a fragment the fibroblast already reads as "rebuild the matrix" — is upstream of the retinoic-acid pathway rather than redundant with it, which is why the two stack cleanly.
The lipidation is the whole point of the molecule. Plain GHK barely penetrates intact skin; bolting a C16 palmitoyl tail onto the N-terminus converts a hydrophilic tripeptide into a stratum-corneum-permeable cosmetic active that actually reaches the fibroblasts it was designed to signal. Concentrations are measured in ppm of finished formula, not mg per subject, and clinical-grade activity has been demonstrated in the single-digit ppm range.
"Palmitoyl tripeptide-1 at 5–6 ppm significantly reduced UVA-induced collagen degradation and enhanced synthesis of type I and III collagen in human skin explants." — Schagen, Cosmetics (2017)
The sections below cover documented Pal-GHK formulation concentrations, the vehicle and pH requirements that determine whether the peptide survives in product, stacking with tretinoin and microneedling protocols, the ~4–16 week timeline before visible change, and the formulation pitfalls (low-pH vitamin C co-application, benzoyl peroxide, water-only vehicles) that quietly destroy the peptide before it ever reaches the dermis.
How Palmitoyl Tripeptide-1 works
Pal-GHK is the lipidated cosmetic derivative of GHK — the matrikine tripeptide (Gly-His-Lys) released from collagen during proteolytic remodelling. The C16 palmitic-acid tail is not pharmacologically active; it is a delivery handle that converts a water-soluble signal peptide into a stratum-corneum-permeable cosmetic active. Once the molecule reaches viable epidermis and dermis, the peptide head behaves as a matrikine — a signal that fibroblasts already read natively as "the matrix is damaged, rebuild it."
The result is upstream activation of the dermal regeneration program rather than direct receptor agonism at a single target. This is why it stacks cleanly with retinoids (which signal through RAR/RXR) and with mechanically different peptides like palmitoyl tetrapeptide-7 — different inputs, same downstream remodelling outcome.
Stratum Corneum Penetration via Lipid Conjugation#
The defining problem with the parent GHK tripeptide is bioavailability: it is hydrophilic, charged at skin pH, and barely traverses the lipid lamellae of the stratum corneum on its own. Palmitoylation raises logP enough to drive passive diffusion through the intercellular lipid pathway, allowing the intact peptide to reach the basal epidermis and upper dermis where fibroblasts live.
"The addition of a palmitoyl chain enhances the delivery of peptides like Pal-GHK through the stratum corneum, improving their bioavailability for dermal fibroblast stimulation." — Veiga, E. et al., Journal of Drug Delivery Science and Technology (2023)
Practically, this is the whole reason Pal-GHK exists as a separate molecule. Plain GHK serums underperform at equivalent ppm because the active never reaches the cells that respond to it.
Matrikine Signalling and ECM Synthesis#
Once delivered, the GHK head engages the fibroblast matrikine-recognition machinery and upregulates the transcription of extracellular matrix components. The signal is broad-spectrum across the ECM rather than collagen-only, which is why the visible result is firmness and density rather than just "thicker skin."
"GHK and its derivatives, including Pal-GHK, act as signaling peptides that upregulate genes responsible for collagen and glycosaminoglycan synthesis and modulate inflammation." — Pickart, L. & Margolina, A., International Journal of Molecular Sciences (2018)
Documented outputs in human dermal fibroblasts include type I, III, and IV collagen, fibronectin, elastin, and glycosaminoglycans (hyaluronic acid and dermatan sulfate). This breadth is what users experience as improved bounce, hydration, and fine-line softening over a 3–4 month timeline — collagen alone would not deliver the hydration effect; the GAG upregulation does.
"Peptides such as Pal-GHK interact with skin cell surfaces to stimulate extracellular matrix production, including fibronectin, elastin, and hyaluronic acid synthesis." — He, B., Wang, F. & Qu, L., Frontiers in Pharmacology (2023)
Suppression of UV-Induced Collagen Degradation#
Pal-GHK is bidirectional — it raises ECM synthesis and blunts ECM breakdown. In ex vivo human skin explants exposed to UVA, low-ppm Pal-GHK measurably reduced photo-induced collagen loss, consistent with downregulation of matrix metalloproteinase (MMP) activity in the irradiated tissue.
"Palmitoyl tripeptide-1 at 5–6 ppm significantly reduced UVA-induced collagen degradation and enhanced synthesis of type I and III collagen in human skin explants." — Schagen, S. K., Cosmetics (2017)
The implication for the looksmaxxing user is that Pal-GHK functions as a defensive layer against photoaging, not just an offensive collagen builder. It pairs naturally with a disciplined SPF routine — sunscreen blocks the insult, Pal-GHK blunts whatever UV exposure does get through.
Anti-Inflammatory Tone and Wound-Healing Modulation#
The GHK head retains modulatory activity on inflammatory signalling carried over from the parent matrikine — influence on TGF-β tone and dampening of IL-1-mediated inflammatory cascades. The clinical signal is subtle in cosmetic use but becomes practically relevant in two scenarios: post-procedure recovery (microneedling, fractional laser, dermarolling), where the wound-healing phase is the entire point, and retinoid co-use, where Pal-GHK softens the barrier disruption tretinoin causes without blunting tretinoin's receptor-level effects.
Why the Ramp Time Is Long#
Every mechanism above operates on fibroblast turnover timescales. Transcriptional upregulation of collagen genes takes days; deposition, cross-linking, and remodelling of new collagen into visible dermal density takes weeks to months. The literature consistently shows meaningful change at 4–6 weeks of twice-daily application, with peak effect at 3–4 months. Users who drop the protocol at two weeks because "nothing happened" are quitting before the biology has run. This is not a perception-driven active like a silicone primer or a hydrating humectant — the result is structural, and structural change is slow.
Protocol
| Level | Dose | Frequency | Notes |
|---|---|---|---|
| Low | 50–100 mg | Twice daily | Documented entry-level range |
| Mid | 100–300 mg | Twice daily | Most commonly studied range |
| High | 300–500 mg | Twice daily | Dosing is expressed as ppm of finished formula, not mg per subject. AM and PM topical application; values shown are ppm in the finished serum. Clinical-grade activity demonstrated from ~5–6 ppm; community/DIY formulations commonly run 100–500 ppm with diminishing returns above ~500 ppm. |
Cycle length & outcomes
Documented cycle
4–16 weeks
Plateau after
16 wks
Cycle Length & Onset#
Pal-GHK is a topical signal peptide, not a parenteral compound — there is no suppression to recover from, no PCT, and no biological reason to cycle off. The "cycle" framing here is really about how long until visible aesthetic change and how to structure ramps when stacking with tretinoin or microneedling. Matrikine signalling operates on fibroblast turnover timescales, so the protocol rewards patience over dose escalation.
Goal-Based Protocols#
Dosing is expressed as ppm of Pal-GHK in the finished serum, applied AM and PM. Anything above ~500 ppm shows diminishing returns; the spend is better directed at complementary peptides (Pal-tetrapeptide-7, GHK-Cu) than at concentration stacking.
| Goal | Cycle Length | Pal-GHK Concentration | Notes |
|---|---|---|---|
| Barrier support / early anti-aging | 8–12 weeks (continuous) | 50–100 ppm | Entry tier; Matrixyl 3000 clone territory |
| General photoaging / fine-line reversal | 12–16 weeks (continuous) | 100–300 ppm | Stack with tretinoin PM, niacinamide AM |
| Aggressive recomp-grade skin protocol | 16+ weeks (continuous) | 300–500 ppm | Paired with tretinoin 0.05–0.1% + monthly microneedling |
| Post-procedure recovery (microneedling, fractional laser) | 72-hour window post-procedure | 200–500 ppm | Applied within 30 min of channel opening, repeat at 12 and 24 h |
| Scalp adjunct (hair stack) | Continuous, between microneedling sessions | 100–300 ppm | Layered into minoxidil / RU58841 vehicle or applied separately |
| Periorbital (thin-skin sites) | Continuous | 50–200 ppm | Lower concentration sufficient; thinner stratum corneum |
Onset Timeline#
The matrikine pathway runs on collagen-remodelling biology, not on receptor kinetics. Expect:
- Weeks 0–2: No visible change. Barrier hydration may improve from the humectant vehicle, which is not the peptide working.
- Weeks 4–6: First detectable changes — fine-line softening, improved skin "snap," subtle firmness on palpation. This is the earliest point at which photographic comparison shows anything real.
- Weeks 8–12: Texture and tone improvement become obvious side-by-side. Pore appearance refines as ECM density increases.
- Weeks 12–16+: Peak effect on photoaging endpoints — collagen I/III deposition has had time to remodel the papillary dermis.
"Palmitoyl tripeptide-1 at 5–6 ppm significantly reduced UVA-induced collagen degradation and enhanced synthesis of type I and III collagen in human skin explants." — Schagen, Cosmetics (2017)
Users who drop the protocol at the 2–3 week mark because "nothing is happening" are quitting before fibroblast output has had a chance to express in the visible epidermis. The literature consistently anchors clinical endpoints at the 8–12 week mark.
Loading & Tapering#
There is no loading phase. The peptide saturates its signalling targets at very low concentrations — in vitro activity is demonstrated from ~0.5 μM (0.3 ppm) and clinical activity from 5–6 ppm — so front-loading higher concentrations does not accelerate onset, it just wastes peptide.
"GHK and its derivatives, including Pal-GHK, act as signaling peptides that upregulate genes responsible for collagen and glycosaminoglycan synthesis and modulate inflammation." — Pickart & Margolina, Int J Mol Sci (2018)
There is also no taper. The protocol is run continuously, indefinitely, the same way tretinoin is run. Discontinuation does not produce a rebound — the new ECM that was deposited stays deposited — but ongoing matrikine signalling is what keeps suppressing MMP-driven collagen breakdown, so most physique-focused users treat Pal-GHK as a permanent foundation layer rather than a finite cycle.
Ramp Considerations When Stacking#
The only meaningful "ramp" decision is when Pal-GHK is being introduced alongside a retinoid:
- Tretinoin-naive users: Establish Pal-GHK first for 2–3 weeks. The matrikine support pre-loads barrier and ECM tone before tretinoin starts disrupting the stratum corneum.
- Tretinoin-experienced users: Pal-GHK can be added immediately; no ramp required. Apply tretinoin first, wait 20–30 minutes, layer Pal-GHK, then occlusive moisturizer.
- Microneedling protocols: Pal-GHK concentration is bumped to the 300–500 ppm tier for the 72 hours surrounding each session. Open microchannels bypass the stratum corneum entirely, so bioavailability spikes — this is the one window where the upper end of the dose ladder is genuinely worth running.
"The addition of a palmitoyl chain enhances the delivery of peptides like Pal-GHK through the stratum corneum, improving their bioavailability for dermal fibroblast stimulation." — Veiga et al., J Drug Deliv Sci Technol (2023)
Monitoring#
No bloodwork. The relevant monitoring is photographic: standardized lighting, distance, and angle at weeks 0, 4, 8, and 12. Mirror-based self-assessment adapts daily and will systematically under-rate slow ECM changes — photos are what reveal whether the protocol is working. A second useful endpoint is barrier feel under tretinoin: if the retinoid is being tolerated at a higher frequency than the prior baseline, the Pal-GHK layer is doing structural work even before fine-line changes are visible.
"The Panel considered the available animal and clinical data and concluded that palmitoyl oligopeptides are safe in the present practices of use and concentration." — Cosmetic Ingredient Review Expert Panel (2018)
The safety ceiling is high enough that the limiting factor on a Pal-GHK protocol is patience and formulation discipline, not dose.
Risks & mistakes
Common (most users)#
Pal-GHK is one of the cleanest topical actives in the cosmetic literature. The CIR Expert Panel reviewed the palmitoyl-oligopeptide class at use-relevant concentrations and concluded the peptides are safe as currently formulated.
"The Panel considered the available animal and clinical data and concluded that palmitoyl oligopeptides are safe in the present practices of use and concentration." — CIR Expert Panel (2018)
At typical formulation concentrations (100–500 ppm), expected effects are minor and almost always vehicle-driven rather than peptide-driven:
- Transient stinging on application — usually traced to the glycol carrier (butylene/pentylene glycol at 30–50%) or to applying onto a compromised barrier. Mitigation: drop application onto fully dry skin, or dilute the serum 1:1 with a bland humectant for the first week.
- Mild flushing or warmth — short-lived, no clinical significance. Resolves as the barrier acclimates over 5–7 days.
- Pilling under sunscreen or makeup — formulation issue, not a side effect per se. Mitigation: thinner application, longer absorption window (3–5 min), or switching to a non-silicone moisturizer layer.
- No visible change in the first 2–4 weeks — not technically a side effect but the single most common complaint. Matrikine signalling operates on fibroblast turnover timescales; meaningful texture and firmness change requires 4–6 weeks minimum, with peak effect at 3–4 months.
Uncommon (dose-dependent or individual)#
- Contact dermatitis from the preservative or carrier — phenoxyethanol, ethylhexylglycerin, or fragrance components account for the overwhelming majority of "peptide reactions" reported in DIY forums. A patch test on the inner forearm for 48 hours before face-wide application identifies this cleanly.
- Reduced potency when stacked with low-pH actives in the same step — co-application with L-ascorbic acid (pH <3.5) or AHA/BHA exfoliants degrades the peptide bond and the histidine imidazole ring. Not a safety issue, but the peptide is wasted. Mitigation: alternate AM/PM, or separate application layers by 15–20 minutes.
- Oxidative degradation with benzoyl peroxide in the same vehicle — same logic. Separate routines or alternate days.
- Apparent "tolerance" / plateau above ~500 ppm — matrikine receptor signalling saturates. Pushing concentration above 0.05% raw peptide gives no further benefit and may compromise serum stability. The protocol calls for adding complementary peptides (palmitoyl tetrapeptide-7, GHK-Cu) rather than escalating Pal-GHK alone.
Rare but serious#
Pal-GHK has no documented serious adverse events in the published cosmetic-safety literature. The theoretical concerns are barrier-mediated rather than peptide-mediated:
- True peptide hypersensitivity — vanishingly rare but possible with any bioactive peptide. Warning signs: persistent erythema, swelling, or vesicle formation at the application site beyond 48 hours. Discontinue immediately.
- Contamination from poorly QC'd raw powder — the larger real-world risk than the molecule itself. Bulk Chinese supplier powder occasionally fails for endotoxin or solvent residue. Sourcing from cosmetic-grade suppliers with COAs (Lotioncrafter, MakingCosmetics, Sederma/Croda for pre-blended Matrixyl 3000) eliminates this category of risk.
- Microbial spoilage of DIY serums — water-phase formulas without an adequate preservative system (phenoxyethanol + ethylhexylglycerin at minimum) will grow gram-negative organisms within days. This is a formulation failure that can cause folliculitis or worse, not a peptide effect.
Hard contraindications#
- Co-application with low-pH vitamin C in the same step — degrades the peptide. Not a safety hazard, but a formulation rule the literature supports.
- Co-application with benzoyl peroxide in the same vehicle — same degradation issue plus oxidative attack on the histidine residue.
- Known peptide hypersensitivity — discontinue and substitute a non-peptide active (niacinamide, panthenol).
- Pregnancy and lactation (precautionary) — cosmetic peptides at use concentrations are considered low-risk, but unlike for retinoids there is no robust dataset either way. Conservative users substitute during this window. This is not a hard biological contraindication like isotretinoin-and-pregnancy; it is a precautionary one driven by absent data.
Gender, PCT, and systemic considerations#
The mechanism is matrikine signalling in dermal fibroblasts and is sex-agnostic — identical formulation concentrations apply across the full user pool. There is no androgenic, estrogenic, or HPTA-suppressive activity; Pal-GHK does not require PCT, does not interact with AAS or SARM protocols, does not affect lipids or blood pressure, and stacks cleanly alongside any systemic compound a user is already running. For the looksmaxxing user this means it is one of the few skin actives that can sit underneath an entire cycle without any monitoring overhead — the only "bloodwork" required is standardized photography at 0, 4, 8, and 12 weeks.
FAQ — Palmitoyl Tripeptide-1
Research & citations
5 studies cited on this page.
Conclusion
Pal-GHK (palmitoyl tripeptide-1) is the signal peptide mainstay across serious aesthetics stacks: a collagen-promoting, barrier-friendly compound with solid topical penetration and proven synergy with tretinoin, microneedling, and peptide cocktails.
Key takeaways:
- Effective dose range: 100–500 ppm (0.01–0.05%) finished formula, applied twice daily; higher concentrations rarely outperform this range
- Application: always topical; best layered under moisturizer and SPF, and applied before or after aggressive actives (tretinoin, acids) in separate steps
- Cycle length: visible skin quality improvements build over 4–16 weeks; plateaus at ~3–4 months of consistent use
- Stacks: clean synergy with tretinoin/retinal (night), copper peptides (alternate routines), and other matrikines (Pal-tetrapeptide-7)
- Safety: extremely low irritation or sensitization rates at cosmetic strengths; avoid co-application with low-pH vitamin C or benzoyl peroxide to preserve activity
- Programming: no PCT, no systemic androgenic/estrogenic effects, no contraindications outside hypersensitivity and the standard pregnancy/lactation caution
For anyone building a maximalist anti-aging or skin-recomp protocol, Pal-GHK's evidence-backed collagen signaling and easy stacking profile make it a foundational peptide in the looksmaxxing arsenal.